Table III.
Patient survival according to different staging systems.
| Staging system | MST (months) | 95% CI | P-value (overall) | P-value in each adjacent group |
|---|---|---|---|---|
| JIS system | 0.001 | |||
| 1 (n=5) | 19.1 | 19.0–19.2 | 1 vs. 2, 0.132 | |
| 2 (n=35) | 11.3 | 5.2–17.5 | 2 vs. 3, 0.088 | |
| 3 (n=76) | 7.6 | 5.2–10.0 | 3 vs. 4, 0.013 | |
| 4 (n=27) | 3.9 | 2.8–5.0 | ||
| BCLC classification system | 0.045 | |||
| A (early stage, n=1) | NT | NT | ||
| B (intermediate stage, n=49) | 11.4 | 7.6–15.1 | B vs. C, 0.017 | |
| C (advanced stage, n=93) | 6.1 | 4.5–7.7 | ||
| TNM classification system | 0.007 | |||
| Stage II (n=7) | 19.0 | 7.1–31.0 | II vs. III, 0.336 | |
| Stage III (n=45) | 11.4 | 6.5–16.3 | III vs. IV, 0.007 | |
| Stage IV (n=91) | 5.7 | 4.5–7.0 | ||
| CLIP scoring system | 0.038 | |||
| 1 (n=54) | 11.8 | 7.7–15.9 | 1 vs. 2, 0.315 | |
| 2 (n=48) | 6.1 | 3.3–8.9 | 2 vs. 3, 0.117 | |
| 3 (n=31) | 4.1 | 1.2–7.1 | 3 vs. 4, 0.895 | |
| 4 (n=10) | 4.3 | 2.8–5.9 | ||
| CUPI scoring system | <0.001 | |||
| Low-risk group (L) (n=106) | 9.4 | 6.3–12.4 | L vs. I, 0.005 | |
| Intermediate-risk group (I) (n=33) | 4.4 | 3.6–5.2 | I vs. H, 0.001 | |
| High-risk group (H) (n=4) | 1.5 | 0.7–2.3 |
JIS, Japan Integrated Staging; BCLC, Barcelona Clinic Liver Cancer; TNM, TUMOR-NODE-METASTASIS; CLIP, Cancer of the Liver Italian Program; CUPI, Chinese University Prognostic Index; MST, median survival time; CI, confidence interval; NT, not tested.